SKC's AMNOG orphan tracker records the most important changes to all orphan drug procedures during and after the AMNOG for an efficient overview on a bimonthly basis.
Highest added benefit, negotiated rebate and much more
The AMNOG orphan tracker provides all essential information about
- New AMNOG orphan drug procedures (active ingredient, trade name, reason for submission, indication)
- Completed AMNOG orphan drug procedures (active ingredient, trade name, indication, highest additional benefit) and
- New rebates for AMNOG orphan drug procedures (active ingredient, trade name, indication, highest added benefit, negotiated rebate)
The SKC Insights offer you further details on exciting AMNOG analyses.
The analyses are generated by data from SKC's proprietary MAIS database.
Download
You would like to download the orphan tracker free of charge? Please enter your contact details in the form. After confirming this, you will immediately receive the link to your chosen edition of the orphan tracker.
AMNOG orphan tracker July / August 2023
ATMPs continue to appear in the AMNOG landscape: for one ATMP each, a new trial has been started (Yescarta®) and completed (Carvykti®) and a rebate has been negotiated (Yescarta®).
AMNOG orphan tracker May / June 2023
The Federal Joint Committee (G-BA) demanded a routine practice data collection for Hemgenix®, two AMNOG procedures have been completed and Novartis announced that the EU approval for Adakveo® will be withdrawn.
AMNOG orphan tracker March / April 2023
ATMPs are becoming ever more present: A new ATMP procedure has been launched with Ebvallo®. Furthermore Roctavian® and Tecartus® were both given a non-quantifiable additional benefit and a reimbursement amount was set for Abecma®.
Full Market Access
Hands-on support throughout the whole process: from strategic positioning all the way to price negotiation, we accompany you seamlessly.
to the top